Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and…
Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million ● Record nine-month revenue of approximately $54.3 million — up 19%
How this was made
The 30-second read
Why it matters
The company reports record preliminary nine-month and Q3 revenue and reaffirmed 2026 revenue outlook of over $90M, which can influence near-term valuation and positioning ahead of the formal 10-Q.
Market read
Fresh preliminary revenue and a reaffirmed full-year target are actionable for traders managing exposure into the next reporting step (Q3 10-Q).
What to watch
The release emphasizes revenue growth but does not provide cost, cash flow, or guidance granularity for Q4; traders may focus on whether the “strongest quarter” expectation is supported by order timing and distribution seasonality.
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Preliminary nine-month revenue increased 19% to approximately $54.3 million and third-quarter revenue reached approximately $17.4 million, while the Company reaffirmed its full-year revenue outlook of over $90 million. The release does not report profitability, cash flow, balance-sheet figures, or segment revenue and results remain preliminary and unaudited.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, third quarter 2026other | ~$17.4M | – | +2% |
| Revenue, nine months to September 30, 2026other | ~$54.3M | – | +19% |
| Revenue, third quarter 2025other | $17.1M | – | 38% |
| Revenue, third quarter 2024other | $12.4M | – | – |
| Revenue, nine months to September 30, 2025other | $45.6M | – | – |
| Revenue, nine months to September 30, 2024other | $40.2M | – | – |
| Revenue, full year 2025other | $65.3M | – | – |
| Revenue, full year 2024other | $54.4M | – | – |
| Cana Laboratories contract manufacturing production pipelineother | more than 32.7 million units | – | – |
| CosmoFarm pharmacy networkother | more than 1,500 pharmacies | – | – |
Full year 2026 outlook
- RevenueOver $90M
- NoteRevenue is expected to surpass $90 million, which would represent growth of approximately 38% over 2025.
- NoteThe Company currently expects the fourth quarter of 2026 to be the strongest quarter in its history.
What drove it
- The Company stated that growth occurred across contract manufacturing, pharmaceutical distribution and proprietary brands.
- Cana Laboratories reached a record production pipeline of more than 32.7 million units.
- CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies that continues to expand.
- Proprietary brands grew in established markets and entered new territories and channels globally.
- The Company cited accelerating sales momentum in the United States.
- The Company expects the fourth quarter to be supported by contract manufacturing orders, seasonal strength in distribution and accelerating sales in the United States.
Concerns
- The 2026 third-quarter and nine-month revenue figures are preliminary and unaudited.
- The preliminary figures are subject to completion of quarter-end financial closing procedures and review, and actual results may differ from the preliminary estimates.
- The Company identified the conversion of contract manufacturing pipeline volumes into production and revenue, including timing, volume and terms of orders under multi-year agreements, as a risk.
- The Company identified the realization of anticipated gross margins and the timing, cost and completion of planned capital investments as risks.
- No profitability, margin, cash flow, liquidity, debt, or segment-revenue results were reported in the release.
What to watch
- Completion of the third-quarter financial closing procedures and the Form 10-Q for the period ended September 30, 2026.
- Whether fourth-quarter revenue becomes the strongest quarter in the Company’s history.
- Execution against the reaffirmed full-year 2026 revenue outlook of over $90 million.
- Conversion of the record contract manufacturing pipeline into production and revenue.
- Distribution volumes, pharmacy-network expansion, proprietary-brand expansion and sales momentum in the United States.
Analysis
Cosmos Health reported preliminary, unaudited revenue of approximately $54.3 million for the nine months ended September 30, 2026, up 19%, or $8.7 million, from $45.6 million in the same period of 2025. The Company described the result as a record and stated that revenue was up 35% against the first nine months of 2024. The nine-month total represented 83% of the record $65.3 million reported for the whole of 2025.
Third-quarter preliminary revenue was approximately $17.4 million, compared with $17.1 million in the third quarter of 2025, a reported increase of 2%. The Company also stated that third-quarter revenue was up 40% from $12.4 million in the third quarter of 2024. Each of the first, second and third quarters of 2026 exceeded the highest revenue previously reported for that respective quarter, according to the release.
Management attributed growth to all core segments, comprising contract manufacturing, pharmaceutical distribution and proprietary brands. Cana Laboratories had a record production pipeline of more than 32.7 million units, while CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies. The release also cited proprietary-brand expansion into new territories and channels, alongside accelerating sales momentum in the United States. Segment revenue and profitability were not disclosed.
The Company reaffirmed its expectation that full-year 2026 revenue will surpass $90 million, which it said would represent growth of approximately 38% over 2025. Management expects the fourth quarter to be the strongest quarter in its history, supported by contract manufacturing orders, seasonal distribution strength and United States sales. The release provides no gross margin, operating expense, earnings, EPS, cash flow, cash, debt, capital-return, or detailed segment financial data, and states that the preliminary revenue estimates remain subject to closing procedures and review.
Management, verbatim
In nine months we have delivered approximately what took us a full year in 2024. Revenue of approximately $54.3 million is 19% ahead of last year, and it comes after a record first quarter, a record second quarter and now a record third quarter — the third achieved against the most demanding comparison in the Company’s history.
Greg Siokas, CEO of Cosmos Health
That growth is coming from every part of the business. Our contract manufacturing pipeline is at a record level, our distribution volumes are the highest we have recorded, and our proprietary brands are growing in their established markets while reaching new ones.
Greg Siokas, CEO of Cosmos Health
The infrastructure we have built over the past several years is now supporting every part of the business, and we enter the final quarter with momentum. We are reaffirming our outlook to surpass $90 million in revenue this year, and we currently expect the fourth quarter to be the strongest in our history.
Greg Siokas, CEO of Cosmos Health
Not in the filing
stated, not guessed- GAAP revenue presentation
- Non-GAAP revenue presentation
- Gross profit and gross margin
- Operating expenses
- Operating income or loss
- Net income or loss
- GAAP EPS
- Non-GAAP EPS
- Tax expense or tax rate
- Operating cash flow
- Free cash flow
- Capital expenditures
- Cash and cash equivalents
- Debt
- Share repurchases
- Dividends
- Segment revenue
- Segment profit or loss
- Revenue for the first quarter of 2026
- Revenue for the second quarter of 2026
- Third-quarter 2026 gross margin, earnings, EPS, cash flow and balance-sheet results
- Prior-quarter comparison for third-quarter 2026 revenue
- Prior-quarter comparison for nine-month 2026 revenue
- Prior outlook document for comparison against actual reported results
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K Item 2.02 furnishing preliminary, unaudited revenue results and a reaffirmed full-year outlook.
Ticker impact
Cosmos Health reports preliminary nine-month revenue of about $54.3M (+19% YoY) and record Q3 revenue of about $17.4M, reaffirming 2026 revenue outlook over $90M.
Likely upward bias as traders price in continued momentum toward the reaffirmed >$90M 2026 revenue outlook.
The filing provides fresh, company-specific operating numbers (preliminary nine-month and Q3 revenue) plus a reaffirmed full-year outlook, which can drive near-term repricing even though figures are preliminary and unaudited.
Market effects
Adds datapoint on performance of vertically integrated healthcare services and branded/pharma distribution models, but likely limited sector-wide read-through.
Primarily company-specific; no explicit regional macro or regulatory catalyst described.
Limited global impact beyond healthcare microcap sentiment, since the disclosure is company financial performance rather than a cross-border policy or supply shock.
Counterpoint
Because the revenue figures are preliminary and unaudited, the market may discount them until the Q3 10-Q confirms margins, segment profitability, and any working-capital swings.
Key entities
- companyCosmos Health Inc.
NASDAQ-listed diversified, vertically integrated global healthcare group reporting preliminary revenue and reaffirming 2026 outlook.
